Time to move forward from ‘‘first-generation’’ prognostic gene signatures in early breast cancer
- نوع فایل : کتاب
- زبان : انگلیسی
- مؤلف : Christine Desmedt Stefan Michiels Benjamin Haibe-Kains Sherene Loi Christos Sotiriou
- چاپ و سال / کشور: 2010
Description
For clinicians, it has been clear for many years that breast cancer patients with the same clinical and pathological characteristics can have diverse clinical outcomes. The advances in the annotations of the genome and the emergence of high throughput gene expression technologies during the last decade have offered researchers powerful means to investigate breast cancer biology and to determine the mechanisms of this clinical heterogeneity [1, 2]. For this purpose, several research groups have developed ‘‘firstgeneration’’ gene expression signatures that could help to better identify which breast cancers are at high or low risk of cancer recurrence, such as MammaPrint [3], the Oncotype Dx ], and the Gene Expression Grade Index [5]. The prognostic value of these three scores have all stood the test in independent validation series [6–8] and are reported to provide further prognostic information to standard clinical and pathological factors, although their precise added value needs to be studied ]. For two of these prognostic scores, prospective worldwide clinical trials are ongoing to estimate their impact on clinical practice for the prescription of adjuvant chemotherapy
Breast Cancer Res Treat (2011) 128:643–645 Received: 23 September 2010 / Accepted: 4 October 2010 / Published online: 16 October 2010 Springer Science+Business Media, LLC. 2010
